Andere talen SinoMab BioScience Limited

Aandelen

3681

HK0000544194

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:20 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,9 ^HKD	0,00%		+0,53%	+13,10%

25/03	SinoMab BioScience Limited rapporteert resultaten voor het gehele jaar eindigend op 31 december 2023	CI
07/02	SinoMab BioScience Limited benoemt Shanchun Wang tot uitvoerend directeur	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy	16/04
SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	25/03
SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	07/02
SinoMab BioScience Raises HK$62.2 Million from Thirteen Share Subscriptions	15/01
SinoMab BioScience Issues 56.8 Million Shares to 15 Investors	15/12
SinoMab Doses First Batch of Subjects in Phase 1 Trial of Atopic Dermatitis Drug in China	28/11
SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China	27/11
China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%	16/11
Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE	15/11
China Accepts New Drug Application of SinoMab's Dermatitis Medication; Shares Rise 3%	12-09-23
SinoMab's IND Application of SM17 has once again Received Approval from NAMP	12-09-23
Sinomab Bioscience Limited announces Change of Non-Executive Directors	06-09-23
Chinese Regulator Accepts License Application for SinoMab's Arthritis Drug	05-09-23
China Accepts SinoMab's Biologics License Application for Arthritis Treatment	05-09-23
SinoMab BioScience Limited Announces National Medical Products Administration Accepts Biologics License Application for SM03 in the Treatment of Rheumatoid Arthritis	05-09-23
SinoMab Bioscience to Shrink Loss in H1	22-08-23
SinoMab BioScience Limited Reports Earnings Results for the Half Year Ended June 30, 2023	21-08-23
SinoMab Bioscience Obtains Clinical Trial Approval in China for Asthma Drug	15-08-23
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP	14-08-23
Sinomab Bioscience Limited Announces IND Approval for Sm17 by Nmpa	14-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen SinoMab BioScience Limited

Aandelen

3681

HK0000544194

Andere talen

Filters